Celltrion Wins Korea Approval For Roche Herceptin Biosimilar
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion gains approval for its second monoclonal antibody biosimilar following a biosimilar of Johnson & Johnson’s Remicade. The approval marks the second entry of a Herceptin biosimilar and the first based on global clinical trials, but Roche believes it is adequately protected against the competition.